window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P3V9EEXXWH');
CEO Corner2021-03-31T15:12:52+00:00

See how our technology creates Endless Possibilities

CEO in Your Corner

Deborah Moorad shares her insights on Nature Technology’s products and services, the industry and the future of genetic engineering.

DID YOU KNOW
CRO mergers are creating biotech “one-stop shops”

June 3rd, 2021|

Four recent clinical research organization (CRO) acquisitions and mergers have indicated a growing trend among biotech manufacturing companies. Charles River acquired Cognate Bioservices, Catalent Paragon acquired Delphi, WuXi Advanced Therapies acquired Oxgene, and Wacker Biotech acquired Genopsis.

DID YOU KNOW
Nanoplasmid Enhances DNA Vaccines for Venezuelan Equine Encephalitis Virus and Ebola Virus

February 18th, 2021|

Nanoplasmid increases efficacy of DNA Vaccines for Venezuelan Equine Encephalitis Virus and Ebola Virus

CASE STUDY
See how Poseida Therapeutics is utilizing the “dual benefits” of our Nanoplasmid™ vector for success

January 13th, 2021|

Data from their ongoing Phase 1 expansion trial using Nanoplasmid demonstrated an improvement in efficacy over standard plasmid and a potentially best-in-class safety profile.

Our Twitter Feed

Recent clinical research organization acquisitions and mergers have indicated a growing trend among biotech manufacturing companies.
Read More Here: https://lnkd.in/evT7uqT
#natx #genetherapy #celltherapy

Today, we honor and remember the men and women who have sacrificed their lives to protect our freedom.

Have a safe Memorial Day!
#MemorialDay

The event is off to a great start. We hope you are tuning in!
#asgct21 #genetherapy #celltherapy #aav #asgct #cartcelltherapy

https://lnkd.in/dSpuGXg

Nanoplasmid™ Dramatically Improves Expression of Retrofits:
The Nanoplasmid (RNA-OUT selectable marker plus R6K origin) replaces antibiotics with sucrose selection, and replaces the promiscuous pUC origin with the host-restricted R6K one.
For more info:https://natx.com/vector-retrofit/

The Nanoplasmid (RNA-OUT selectable marker plus R6K origin) replaces antibiotics with sucrose selection, and replaces the promiscuous pUC origin with the host-restricted R6K one. It is regulatory compliant and smaller in size (<500 bp) than conventional marker/ORIs.

Load More...
Go to Top